Show simple item record

dc.contributor.authorSaunders, Mark P
dc.contributor.authorWilson, R
dc.contributor.authorPeeters, M
dc.contributor.authorSmith, R
dc.contributor.authorGodwood, A
dc.contributor.authorOliver, S
dc.contributor.authorVan Cutsem, E
dc.date.accessioned2009-03-11T09:31:10Z
dc.date.available2009-03-11T09:31:10Z
dc.date.issued2009-01-29
dc.identifier.citationVandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre Phase I study. 2009: Cancer Chemother. Pharmacol.en
dc.identifier.issn1432-0843
dc.identifier.pmid19184020
dc.identifier.doi10.1007/s00280-008-0914-4
dc.identifier.urihttp://hdl.handle.net/10541/53953
dc.description.abstractPURPOSE: The safety and tolerability of vandetanib (ZACTIMAtrade mark; ZD6474) plus FOLFIRI was investigated in patients with advanced colorectal cancer (CRC). METHODS: Patients eligible for first- or second-line chemotherapy received once-daily oral doses of vandetanib (100 or 300 mg) plus 14-day treatment cycles of FOLFIRI. RESULTS: A total of 21 patients received vandetanib 100 mg (n = 11) or 300 mg (n = 10) + FOLFIRI. Combination therapy was well tolerated at both vandetanib dose levels. There were no DLTs in the vandetanib 100 mg cohort and one DLT of hypertension (CTCAE grade 3) in the 300 mg cohort. The most common adverse events were diarrhoea (n = 20), nausea (n = 12) and fatigue (n = 10). Two patients (one in each cohort) discontinued vandetanib due to adverse events (rash, 100 mg cohort; hypertension, 300 mg cohort). There was no apparent pharmacokinetic interaction between vandetanib and FOLFIRI. Preliminary efficacy results included two confirmed partial responses in the 100 mg cohort and 9 patients with stable disease >/=8 weeks (100 mg, n = 7; 300 mg, n = 2). CONCLUSIONS: Once-daily vandetanib (100 or 300 mg) in combination with a standard FOLFIRI regimen was generally well tolerated in patients with advanced CRC.
dc.languageENG
dc.language.isoenen
dc.subjectVandetaniben
dc.subjectFOLFIRIen
dc.subjectColorectal Canceren
dc.subjectColorectal Adenocarcinomaen
dc.titleVandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre Phase I study.en
dc.typeArticleen
dc.contributor.departmentChristie Hospital, Wilmslow Road, Manchester, M20 4BX, UK, Mark.Saunders@christie.nhs.uk.en
dc.identifier.journalCancer Chemotherapy and Pharmacologyen
html.description.abstractPURPOSE: The safety and tolerability of vandetanib (ZACTIMAtrade mark; ZD6474) plus FOLFIRI was investigated in patients with advanced colorectal cancer (CRC). METHODS: Patients eligible for first- or second-line chemotherapy received once-daily oral doses of vandetanib (100 or 300 mg) plus 14-day treatment cycles of FOLFIRI. RESULTS: A total of 21 patients received vandetanib 100 mg (n = 11) or 300 mg (n = 10) + FOLFIRI. Combination therapy was well tolerated at both vandetanib dose levels. There were no DLTs in the vandetanib 100 mg cohort and one DLT of hypertension (CTCAE grade 3) in the 300 mg cohort. The most common adverse events were diarrhoea (n = 20), nausea (n = 12) and fatigue (n = 10). Two patients (one in each cohort) discontinued vandetanib due to adverse events (rash, 100 mg cohort; hypertension, 300 mg cohort). There was no apparent pharmacokinetic interaction between vandetanib and FOLFIRI. Preliminary efficacy results included two confirmed partial responses in the 100 mg cohort and 9 patients with stable disease >/=8 weeks (100 mg, n = 7; 300 mg, n = 2). CONCLUSIONS: Once-daily vandetanib (100 or 300 mg) in combination with a standard FOLFIRI regimen was generally well tolerated in patients with advanced CRC.


This item appears in the following Collection(s)

Show simple item record